Ovarian cancer antigen CA125 is encoded by the MUC16 mucin gene

  title={Ovarian cancer antigen CA125 is encoded by the MUC16 mucin gene},
  author={Beatrice W. T. Yin and Ann M. Dnistrian and Kenneth O. Lloyd},
  journal={International Journal of Cancer},
Serum assays based on the CA125 antigen are widely used in the monitoring of patients with ovarian cancer; however very little is known about the molecular nature of the CA125 antigen. We recently cloned a partial cDNA (designated MUC16) that codes for a new mucin that is a strong candidate for being the CA125 antigen. This assignment has now been confirmed by transfecting a partial MUC16 cDNA into 2 CA125‐negative cell lines and demonstrating the synthesis of CA125 by 3 different assays. Of… 
CA125 in ovarian cancer.
The CA125 gene, MUC16, was cloned 20 years after the protein discovery and revealed a very complex and unusual glycoprotein structure, suggesting an immunological role and evidence points toward CA125 function in the induction of materno-fetal tolerance through the alteration of natural killer phenotype.
MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress
An in-depth review of the literature is provided to highlight the importance of CA125 as a prognostic and diagnostic marker for ovarian cancer and the increasing body of literature describing the biological role of MUC16 in the progression and metastasis of ovarian tumors.
Novel Monoclonal Antibodies Against the Proximal (Carboxy-Terminal) Portions of MUC16
Novel-specific antibodies to the carboxy-terminal portion of MUC16 retained by the cell proximal to the putative cleavage site are raised and development of such antibodies may be useful for the characterization of M UC16 biology and allow for future studies in targeted therapy and diagnostics.
Characterization of binding epitopes of CA125 monoclonal antibodies.
It is suggested that binding epitopes of mAbs OC125 and M11 are dependent on conformation but not on glycosylation, which opens the way for vaccine studies.
Expression of the Carboxy-Terminal Portion of MUC16/CA125 Induces Transformation and Tumor Invasion
The carboxy-terminal portion of the MUC16/CA125 protein is oncogenic in NIH/3T3 cells, increases invasive tumor properties, activates the AKT and ERK pathways, and contributes to the biologic properties of ovarian cancer.
The evolving role of MUC16 (CA125) in the transformation of ovarian cells and the progression of neoplasia.
Following the journey of the molecule from pre-malignant states to advanced stages of disease it demonstrates its behaviour, in relation to the phenotypic shifts and progression of ovarian cancer, and presents proposed differences of MUC16 structure in normal/benign conditions and epithelial ovarian malignancy.
Understanding the Unique Attributes of MUC16 (CA125): Potential Implications in Targeted Therapy.
How the understanding of the basic biologic processes involving MUC16 influences the approach toward M UC16-targeted therapy is provided.
The Role of MUC16 Mucin (CA125) in the Pathogenesis of Ovarian Cancer
The present review will discuss the unique structure and functional roles of MUC16 in OC.
Development and characterization of carboxy-terminus specific monoclonal antibodies for understanding MUC16 cleavage in human ovarian cancer
It is demonstrated that M UC16 is cleaved in ovarian cancer cells and that the cleaved MUC16 subunits remain associated with each other and may also serve as potential therapeutic agents for treatment of ovarian cancer.
Roles of CA125 in diagnosis, prediction, and oncogenesis of ovarian cancer.


Molecular Cloning of the CA125 Ovarian Cancer Antigen
The isolation of a long, but partial, cDNA that corresponds to the CA125 antigen and the deduced amino acid sequence has many of the attributes of a mucin molecule and was designated CA125/MUC16 (gene MUC16).
New monoclonal antibodies identify the glycoprotein carrying the CA 125 epitope.
Isolation and characterization of ovarian cancer antigen CA 125 using a new monoclonal antibody (VK‐8): identification as a mucin‐type molecule
Although this result, and other immunochemical data, indicate that OC125, the original MAb to CA125, and VK‐8 antibodies detect epitopes on the protein portion of the molecule, the involvement of carbohydrate cannot be ruled out.
CA 125: fundamental and clinical aspects.
The major contribution of CA 125 is in the monitoring of tumor response to chemotherapy, where it is valuable in detecting those patients with an inadequate response to the chosen treatment, and in the follow-up during and after therapy.
CA 125: The past and the Future
An algorithm has been developed that estimates the risk of ovarian cancer (ROC) based upon the level and trend of CA 125 values and a major trial has been initiated that uses the ROC algorithm to trigger transvaginal sonography and/or subsequent laparotomy.
Specificity and affinity of 26 monoclonal antibodies against the CA 125 antigen: first report from the ISOBM TD-1 workshop. International Society for Oncodevelopmental Biology and Medicine.
  • K. Nustad, R. Bast, J. Hilgers
  • Biology
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
  • 1996
The specificity of 26 monoclonal antibodies against the CA 125 antigen was investigated in two phases of the ISOBM TD-1 workshop and it is concluded that the CA125 antigen carries only two major antigenic domains, which classifies the antibodies as OC125- like (group A) or M11-like (group B).
More than 15 Years of CA 125: What is Known about the Antigen, Its Structure and Its Function
A model of a theoretical CA 125 molecule is presented to stimulate discussion on the regulation of CA 125 synthesis, its secretion and its structural configuration and it will provide a focus of attention until the CA 125 gene is cloned and the real molecule is described.
Reactivity of a monoclonal antibody with human ovarian carcinoma.
A murine monoclonal antibody (OC125) has been developed that reacts with each of six epithelial ovarian carcinoma cell lines and with cryopreserved tumor tissue from 12 of 20 ovarian cancer patients.
The CA 125 Gene: An Extracellular Superstructure Dominated by Repeat Sequences
CA 125 has long presented problems to both clinicians and investigators because there was no definitive information on its structure and function. Here, we describe our work on cloning the CA 125
[Clinical value of the estimation of growth kinetics of primary ovarian cancer recurrences by CA125 doubling time].
This work shows that dt was an essential predictive parameter of ovarian epithelial tumor recurrences, and among all early clinical, histological, biological and therapeutic parameters, the initial CA125 half-life calculated during the third courses of the first-line chemotherapy is the unique predictive parameters of dt.